Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2025)

Crinetics Pharmaceuticals has reported Other Non-Current Liabilities over the past 2 years, most recently at $3.2 million for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $3.2 million for Q4 2025, up 290.83% from a year ago — trailing twelve months through Dec 2025 was $3.2 million (up 290.83% YoY), and the annual figure for FY2025 was $3.2 million, up 290.83%.
  • Other Non-Current Liabilities for Q4 2025 was $3.2 million at Crinetics Pharmaceuticals, up from $2.9 million in the prior quarter.
  • Over the last five years, Other Non-Current Liabilities for CRNX hit a ceiling of $3.2 million in Q4 2025 and a floor of $202000.0 in Q2 2024.